What a diode array adds, and why the certificate never shows it

The detector in almost every purity determination in this market is an ultraviolet absorbance detector, and the wavelength it is set to determines the population of impurities that can exist as far as the report is concerned. The amide bond absorbs strongly in the region around two hundred and ten to two hundred and twenty nanometres, which means a method reading there responds to essentially any peptide-bonded species, including short fragments with no aromatic residues. The aromatic side chains of tryptophan, tyrosine and phenylalanine absorb near two hundred and eighty nanometres, where the backbone contributes almost nothing.

Wavelength, and the impurities it decides to see

The amide bond has a strong absorbance in the far ultraviolet, and peptide methods conventionally read at two hundred and fourteen or two hundred and twenty nanometres to exploit it. The virtue is universality: every peptide-bonded species responds, roughly in proportion to the number of bonds it contains, which is as close to a mass-proportional response as ultraviolet detection gets. The cost is that solvents, additives and dissolved gases also absorb there, so baseline noise is higher and mobile-phase quality matters more.

Aromatic side chains absorb near two hundred and eighty nanometres, where the backbone is essentially transparent. A method reading there sees only species containing tryptophan, tyrosine or phenylalanine, on a quiet baseline. For a peptide with a single tryptophan it is a selective and elegant way to track that residue. As a purity method it is close to indefensible, because any fragment that has lost the aromatic residue is invisible regardless of how much is present.

Certificates reading at two hundred and eighty nanometres do circulate. Readers have sent us several. The Journal’s position is not that such a method is wrong but that it answers a different question, that a purity figure derived from it is not comparable with one derived at two hundred and fourteen, and that the wavelength is one line and belongs on the page. A diode-array detector records everything at once and makes the entire argument moot, which is why we ask whether one was used.

Equal area is not equal mass

Area per cent contains an assumption that is almost never stated: that each species contributes detector signal in proportion to its mass, at the same rate as the parent. In ultraviolet detection that requires equal absorptivity per unit mass, and peptide impurities frequently do not oblige. A truncated fragment missing several amide bonds absorbs less at two hundred and fourteen nanometres per unit mass than the parent; a fragment missing a tryptophan absorbs dramatically less at two hundred and eighty. An oxidation product may absorb slightly more.

The direction of the resulting error is not fixed, which is what makes it awkward. Where impurities under-respond, area per cent overstates purity. Where they over-respond, it understates it. Regulated pharmaceutical practice addresses this by determining relative response factors for known impurities and applying correction factors, or by using an alternative detection principle with a more nearly uniform response — charged aerosol detection and mass-based approaches both aim at this.

Nothing in this market applies correction factors, and it would be unreasonable to expect it, since doing so requires isolated impurity standards. What is reasonable is that the assumption be visible. A purity figure is an area ratio, area ratios approximate mass ratios, and the approximation has not been quantified for the sample in question. Two sentences on a certificate would say so, and would make the number more useful rather than less.¹

Injection load, linearity and the flattened peak

A detector responds linearly to concentration over a defined range and then stops. Overload the column or saturate the detector with too much sample and the main peak flattens at the top, its apex broadens, and its integrated area no longer represents the quantity present. Since the main peak is the numerator and dominates the denominator, distorting it distorts the purity figure — usually downwards, because the flattened peak loses area relative to a properly loaded one.

There is a competing pressure, and it is the reason overloading happens. Small impurities near the reporting threshold need adequate signal-to-noise to be integrated at all, and the way to raise their signal is to inject more sample. A laboratory hunting for 0.05 per cent impurities is tempted towards a load that compromises the main peak. The correct answer in regulated practice is two injections: a small load for the main peak and a larger one for the related-substances profile, with the results combined.

Column overload is a separate phenomenon from detector saturation and produces a characteristic asymmetric fronting peak. Both are visible on the chromatogram to anybody who is shown it, which is one of several reasons the Journal asks for the trace rather than the number. A purity figure calculated from a distorted main peak is arithmetically correct and analytically meaningless, and the only way to know is to look.²

The threshold, and what falls below it

Integration software applies a threshold — expressed as a slope sensitivity, an area cut-off, a height cut-off or some combination — below which a feature in the trace is treated as baseline noise and not integrated. The setting is necessary: without it, every fluctuation would be reported as an impurity and the result would be dominated by noise. The setting is also consequential, because a great many real, small, closely related species live in the region between the two conventional choices.

The arithmetic is easy to underestimate. A well-made peptide preparation may carry twenty or thirty related species each between two-hundredths and a tenth of one per cent — deletion sequences, deamidated and oxidised forms, epimers. Reported individually against a low threshold they might total a percentage point or more. Discarded against a high threshold they total zero. Two laboratories reporting 99.4 and 98.3 on the same lot may have measured the same chromatogram and disagreed only about which features are noise.

The Journal has asked all four independent services what threshold their standard peptide report uses. Two answered with a figure. One answered that it depends on the method and offered to supply the value per report, which is a better answer than a fixed number. One did not answer. We regard the threshold as second only to the gradient in importance and, like the gradient, it is a single value that whoever produced the document already knows.

Reference standards, and what a retention time proves

A reference standard is material of established identity, purity and content against which an analysis is calibrated. Compendial standards are characterised by collaborative study and supplied with a certificate stating their assigned content. In-house standards are qualified against a compendial standard where one exists, or characterised by a battery of orthogonal methods where one does not. For most research peptides there is no compendial standard, which means every claim of identity or assay in this market ultimately rests on somebody’s in-house material.

What a matched retention time supports is worth stating precisely: it supports the inference that the sample and the standard behave identically in this separation. That is real evidence of consistency between two materials. It is not identification, because retention time is not unique — deletion sequences, epimers and unrelated compounds of similar hydrophobicity can share a retention window, and the peak width of a peptide separation is wide enough to hide a great deal.

Two consequences follow for reading a certificate. A report stating that identity was confirmed by comparison of retention time with a reference standard has told you about consistency, not identity. And a purity figure quoted as an assay — a percentage of label claim — requires a quantitative standard of known content, which is a much stronger claim than area per cent and should be labelled differently. The two are routinely printed in the same field.³

A note on method and sourcing

The compendial and regulatory material in this piece is taken from the current general chapters on chromatography and on validation of compendial procedures, from the European Pharmacopoeia chapters on liquid chromatography and on chromatographic separation techniques, and from the harmonised guidelines on analytical validation, on impurities and on specifications for biotechnological products, all read in the original. The separation science is drawn from the chromatography literature, with the peptide-specific behaviour cited where it differs from small-molecule practice.

Where the Journal reports a number it obtained, it states the number of vials, the number of laboratories, whether the vials came from one lot, whether the laboratories knew, and what method parameters were disclosed to us. Where we quote a figure from a certificate we state whether the method was disclosed on it. Where a laboratory or a company answered our questions we distinguish an answer from a refusal and a refusal from a non-response.

Nothing in this department is a recommendation to buy, use or avoid anything. The compounds referred to are sold for research use only and are not approved for human use in any jurisdiction. Corrections and disputes go to standards@compoundjournal.com. Readers with certificates or chromatograms they would like read should write to letters@compoundjournal.com; we do not identify the source of anything sent to us, and we do not publish a reader’s name without permission.

Ruggedness testing, and what it protects against

Ruggedness testing in regulated pharmaceutical practice submits a method to deliberate small changes in conditions—temperature within a range, flow rate within a percentage, mobile-phase pH within a fraction, column lot change—and confirms that the method gives acceptably similar answers under all those conditions. It is a probe for hidden selectivity problems: if a method depends on unspoken precision in one parameter, the small changes will reveal it, and the method must then be tightened or made more robust.⁴ A method that survives ruggedness testing is one that works because of its design choices, not because of luck.

Ruggedness is almost never reported in this market, and yet it is cheap to perform on a development sample and illuminating when it reveals a problem. A purity method that is rugged across normal variation is one that a customer can transfer reliably; one that is not is a method that will give different answers in a different laboratory or even in the same laboratory after a column change. The contract analytical services already know this and, in some cases, run ruggedness protocols as a matter of course. Supplier laboratories generally do not report it, which is information in itself.

The full spectrum, recorded and discarded

A diode-array detector records ultraviolet absorbance across a wavelength range—commonly 200 to 400 nanometres—at every point in the chromatogram. From that data, two things of immediate value can be extracted. First, the spectrum can be examined at each peak to confirm spectral homogeneity—a pure peak has a spectrum that does not drift across its width, while a co-eluted pair shows a spectrum that changes. Second, the full spectrum can be plotted to reveal absorbers that were not visible at the single monitoring wavelength.⁵ A 254-nanometre impurity in a sample monitored at 280 nanometres is invisible in the 214-nanometre chromatogram and is therefore invisible in the purity report, until a diode-array scan reveals it.

Almost no research-peptide certificate prints this information. The data exists—it is generated automatically—and its absence from the report is a formatting decision, not a technical limitation. The usefulness of seeing the full spectrum would be apparent on the first certificate where it resolves an otherwise inexplicable discrepancy between the purity and the mass-balance calculation. It is one of the few changes to the standard format that costs nothing and adds information the reader genuinely needs.

Dissolution, pH and what happens before the injection

A peptide in a vial exists in whatever state the manufacturer left it. Reconstituted in water, a hydrophobic sequence may not dissolve completely and the chromatogram will show particles or aggregates. Reconstituted in an acidic buffer, the same sequence dissolves and the chromatogram shows monomer. The purity figure—and the mass balance—changes accordingly. Sample preparation is not one of the twelve values that belong on a method disclosure, and yet it is one of the most consequential, because it determines what population the peptide is actually in when the injection happens.³

The trade addresses this by assuming that samples are dissolved in the mobile phase or its aqueous component, and the assumption is sometimes true and sometimes false. A certificate that states how the sample was dissolved, at what concentration, in what solvent and after what incubation time, is one that can be repeated. A certificate that does not is one that will produce different results if the receiving laboratory uses different dissolution practice, which is particularly consequential for poorly soluble sequences.

We will keep buying material, submitting it, and printing the method alongside the number, including on the occasions when our own design turns out to have been inadequate. Two of the exercises reported in this department have had their limitations pointed out by readers before we noticed them ourselves, and both corrections are in the log.